Cinacalcet versus parathyroidectomy for primary hyperparathyroidism: a single centre experienc
Abstract
Background and Aim.
Parathyroidectomy is the standard treatment for primary hyperparathyroidism (PHPT). Cinacalcet, an allosteric modulator of the calcium sensing receptor, has been shown to be effective in reducing serum calcium levels and it has gained prominence as a non-invasive treatment in PHTH. Aim of the study was to compare the efficacy and tolerability of medical therapy vs surgery in a cohort of PHPT patients.
Patients and Methods.
The study included 63 consecutive subjects (14 men and 49 women, median age 62.4 ± 12 yr) with PHPT: 50 subjects (40 F and 10 M, ratio F/M 4:1; median age 59.6 ± 16.6 years, range 37-82) underwent parathyroidectomy, while 13 (9 F and 4 M, ratio F/M 2.5:1, median age 76.5 ± 6.2 years, range 64-83), who were ineligible for surgery, were treated with cinacalcet. Cinacalcet was administered at increasing dosages until normal serum calcium was reached or side effects occurred. Serum calcium and PTH was measured and adverse events were monitored during a 12 month-duration follow-up.
Results.
All patients who had undergone parathyroidectomy normalized both serum calcium and PTH levels after surgery (P=0.001 vs baseline) and none of them experienced persistent and/or recurrent PHPT during follow-up. In the group under cinacalcet therapy, serum calcium significantly decreased in all patients within 4 weeks (P = 0.01 vs baseline) and normalized in all patients at prolonged follow-up (P=0.001 vs baseline), while PTH slightly decreased during follow-up (P=0.878 vs baseline) and never reached a normal value.
Conclusion.
Surgical treatment is curative and safe in most cases of PHPT. Cinacalcet represents an effective therapeutic option, from the perspective of hypercalcemia improvement, in PHPT patients who have contraindications to surgery or persistent PHPT after surgery.
Keywords
Full Text:
PDFReferences
1. Marcocci, C., Cetani, F. (2011). Primary hyperparathyroidism. N Engl J Med, 365, 2389–2397.
2. Yeh, M.W., Ituarte, P.H., Zhou, H.C., Nishimoto, S., Liu, I.L., Harari, A., Haigh, P.I., Adams, A.L. (2013). Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab, 98(3), 1122-1129.
3. Pepe, J., Cipriani, C., Pilotto, R., De Lucia, F., Castro, C., Lenge, L., Russo, S., Guarnieri, V., Scillitani, A., Carnevale, V., D'Erasmo, E., Romagnoli, E., Minisola, S. (2011). Sporadic and hereditary primary hyperparathyroidism. J Endocrinol Invest, 34(7), 40-44.
4. Cetani, F., Saponaro, F., Borsari, S., Marcocci, C. (2019). Familial and Hereditary Forms of Primary Hyperparathyroidism. Front Horm Res, 51, 40-51.
5. Udelsman, R., Lin, Z., Donovan, P. (2011) The superiority of minimally invasive parathyroidectomy based on 1650 consecutive patients with primary hyperparathyroidism. Annals of Surgery, 253, 585–591.
6. Bilezikian, J.P., Brandi, M.L., Eastell, R., Silverberg, S.J., Udelsman, R., Marcocci, C., Potts, J.T. Jr. (2014). Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 99(10), 3561-3569.
7. Hedback, G., Oden, A. (2003). Recurrence of hyperparathyroidism: a long-term follow-up after surgery for primary hyperparathyroidism. Eur J Endocrinol, 148, 413–421
8. Wells, Jr. S.A., Debenedetti, M.K., Doherty, G.M. (2002). Recurrent or persistent hyperparathyroidism. J Bone Miner Res, 17(2), 158–162.
9. Nemeth, E.F., Heaton, W.H., Miller, M., Fox, J., Balandrin, M.F., Van Wagenen, B.C., Colloton, M., Karbon, W., Scherrer, J., Shatzen, E., Rishton, G., Scully, S., Qi, M., Harris, R., Lacey, D., Martin, D. (2004). Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther, 308, 627–635.
10. Peacock, M., Bilezikian, J.P., Klassen, P.S., Guo, M.D., Turner, S.A., Shoback, D. (2005). Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab, 90, 135–141.
11) Silverberg, S.J., Rubin, M.R., Faiman, C., Peacock, M., Shoback, D.M., Smallridge, R.C., Schwanauer, L.E., Olson, K.A., Klassen, P., Bilezikian, J.P. (2007). Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma. J Clin Endocrinol Metab, 92, 3803–3808.
12. Falchetti, A., Cilotti, A., Vaggelli, Masi, L., Amedei, A., Cioppi, F., Tonelli, F., Brandi, M.L. (2008). A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet. Nat Clin Pract Endocrinol Metab, 4, 351–357.
13. Walker, M.D., Silverberg, S.J. (2018). Primary hyperparathyroidism. Nat Rev Endocrinol, 14(2), 115–125.
14. Makras, P., Anastasilakis, A.D. (2017). Bone disease in primary hyperparathyroidism. Metabolism, 80, 57-65.
15. Manaka, K., Sato, J., Kinoshita, Y., Ito, N., Fujita, M., Iiri, T., Nangaku, M., Makita, N. (2019). Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J, 19 [Epub ahead of print]
16. Campennì, A., Ruggeri, R.M., Sindoni, A., Giovinazzo, S., Calbo, L., Ieni, A., Monaco, M., Tuccari, G., Benvenga, S., Baldari, S.(2012).Parathyroid carcinoma as a challenging diagnosis: report of three cases. Hormones (Athens), 11(3), 368-76
17. Campennì, A., Ruggeri, R.M., Sindoni, A., Giovinazzo, S., Calbo, E., Ieni, A., Calbo, L., Tuccari, G., Baldari, S., Benvenga, S. (2012). Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab, 30(3), 367-372.
18. Cetani, F., Saponaro, F., Marcocci, C. (2018) Non-surgical management of primary hyperparathyroidism. Best Pract Res Clin Endocrinol Metab, 32(6), 821-835
19. Cetani, F., Saponaro, F., Banti, C., Cianferotti, L., Vignali, E., Chiavistelli, S., Viccica, G., Pinchera, A., Marcocci, C. (2012). Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest, 35(7), 655-660.
20. Peacock, M., Bilezikian, J.P., Bolognese, M.A., Borofsky, M., Scumpia, S., Sterling, L.R., Cheng, S., Shoback, D. (2011). Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab, 96(1), 9-18.
21. Saponaro, F., Faggiano, A., Grimaldi, F., Borretta, G., Brandi, M.L., Minisola, S., Frasoldati, A., Papini, E., Scillitani, A., Banti, C., Del Prete, M., Vescini, F., Gianotti, L., Cavalli, L., Romagnoli, E., Colao, A., Cetani, F., Marcocci, C. (2013). Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicentre group. Clin Endocrinol (Oxf), 79(1), 20-26.
Schwarz, P., Body, J.J., Cáp, J., Hofbauer, L.C., Farouk, M., Gessl, A., Kuhn, J.M., Marcocci, C., Mattin, C., Muñoz Torres, M., Payer, J., Van De Ven, A., Yavropoulou, M., Selby, P. (2014). The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol, 171(6), 727-735.
DOI: https://doi.org/10.6092/1828-6550/APMB.107.2.2019.OS2
Refbacks
- There are currently no refbacks.
Copyright (c) 2019 Salvatore Giovinazzo, Alfredo Campennì, Antonio Ieni, Francesco Barca, Salvatore Cannavò, Rosaria Maddalena Ruggeri
This work is licensed under a Creative Commons Attribution 4.0 International License.